Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials
MS Popoviciu, L Păduraru, G Yahya… - International journal of …, 2023 - mdpi.com
Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …
growing global concern. These comorbidities include type 2 diabetes, hypertension …
Obesity in Prader–Willi syndrome: Physiopathological mechanisms, nutritional and pharmacological approaches
G Muscogiuri, L Barrea, F Faggiano… - Journal of …, 2021 - Springer
Prader–Willi syndrome (PWS) is a genetic disorder caused by the lack of expression of
genes on the paternally inherited chromosome 15q11. 2-q13 region. The three main genetic …
genes on the paternally inherited chromosome 15q11. 2-q13 region. The three main genetic …
Preparation, structural properties, and in vitro and in vivo activities of peptides against dipeptidyl peptidase IV (DPP-IV) and α-glucosidase: a general review
X Mu, R Wang, C Cheng, Y Ma, Y Zhang… - Critical Reviews in Food …, 2024 - Taylor & Francis
Diabetes is one of the fastest-growing and most widespread diseases worldwide.
Approximately 90% of diabetic patients have type 2 diabetes. In 2019, there were about 463 …
Approximately 90% of diabetic patients have type 2 diabetes. In 2019, there were about 463 …
Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases
EM Rhea, A Babin, P Thomas, M Omer, R Weaver… - Tissue …, 2024 - Taylor & Francis
Background A number of peptide incretin receptor agonists (IRAs) show promise as
therapeutics for Alzheimer's disease (AD) and Parkinson's disease (PD). Transport across …
therapeutics for Alzheimer's disease (AD) and Parkinson's disease (PD). Transport across …
The race to bash NASH: emerging targets and drug development in a complex liver disease
FA Romero, CT Jones, Y Xu, M Fenaux… - Journal of medicinal …, 2020 - ACS Publications
Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease
(NAFLD) characterized by liver steatosis, inflammation, and hepatocellular damage. NASH …
(NAFLD) characterized by liver steatosis, inflammation, and hepatocellular damage. NASH …
Dissecting the physiology and pathophysiology of glucagon-like peptide-1
S Paternoster, M Falasca - Frontiers in endocrinology, 2018 - frontiersin.org
An aging world population exposed to a sedentary life style is currently plagued by chronic
metabolic diseases, such as type-2 diabetes, that are spreading worldwide at an …
metabolic diseases, such as type-2 diabetes, that are spreading worldwide at an …
Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency
Type 2 diabetes mellitus (T2DM) is increasing in global prevalence and is associated with
serious health problems (eg, cardiovascular disease). Various treatment options are …
serious health problems (eg, cardiovascular disease). Various treatment options are …
Cold exposure and oral delivery of GLP-1R agonists by an engineered probiotic yeast strain have antiobesity effects in mice
Advanced microbiome therapeutics (AMTs) holds promise in utilizing engineered microbes
such as bacteria or yeasts for innovative therapeutic applications, including the in situ …
such as bacteria or yeasts for innovative therapeutic applications, including the in situ …
Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: a randomized …
NA Di Prospero, J Yee, ME Frustaci… - Clinical …, 2021 - Wiley Online Library
Weight loss has been shown to improve metabolic parameters and cardiovascular risk in
people with type 2 diabetes mellitus (T2DM). This phase 2 study evaluated the safety and …
people with type 2 diabetes mellitus (T2DM). This phase 2 study evaluated the safety and …
Concept for a unidirectional release mucoadhesive buccal tablet for oral delivery of antidiabetic peptide drugs such as insulin, glucagon-like peptide 1 (GLP-1), and …
Injectable peptides such as insulin, glucagon-like peptide 1 (GLP-1), and their agonists are
being increasingly used for the treatment of diabetes. Currently, the most common route of …
being increasingly used for the treatment of diabetes. Currently, the most common route of …